Document is current
Any future updates will be listed below
-
Authors
Lutz, Raphael
Grünschläger, Florian
Simon, Malte
Awwad, Mohamed H. S. https://orcid.org/0000-0003-4514-7199
Bauer, Marcus
Yousefian, Schayan https://orcid.org/0000-0003-0902-0369
Beumer, Niklas https://orcid.org/0000-0001-6538-0217
Jopp-Saile, Lea
Sedlmeier, Anastasia https://orcid.org/0009-0002-0418-2131
Solé-Boldo, Llorenç
Avanesyan, Bogdan https://orcid.org/0009-0004-2547-6598
Vonficht, Dominik
Stelmach, Patrick https://orcid.org/0009-0000-5270-4761
Steinbuss, Georg
Boch, Tobias
Steiger, Simon https://orcid.org/0000-0002-4845-5042
Baertsch, Marc-Andrea
Prokoph, Nina
Rippe, Karsten https://orcid.org/0000-0001-9951-9395
Durie, Brian G. M.
Wickenhauser, Claudia
Trumpp, Andreas https://orcid.org/0000-0002-6212-3466
Müller-Tidow, Carsten https://orcid.org/0000-0002-7166-5232
Hübschmann, Daniel https://orcid.org/0000-0002-6041-7049
Weinhold, Niels https://orcid.org/0000-0002-5464-3234
Raab, Marc S. https://orcid.org/0000-0003-4181-6922
Brors, Benedikt https://orcid.org/0000-0001-5940-3101
Goldschmidt, Hartmut https://orcid.org/0000-0003-0961-0035
Imbusch, Charles D. https://orcid.org/0000-0003-4920-551X
Hundemer, Michael https://orcid.org/0000-0002-5596-2405
Haas, Simon https://orcid.org/0000-0001-9227-2051
- License Information
-
More Information
Article History
Received: 16 October 2023
Accepted: 14 November 2024
First Online: 29 November 2024
Competing interests
: C.M.-T. received research funding from Bioline RX and Pfizer. M.B. has served as a consultant for Takeda and Novartis; received research funding from Novartis and travel support from Celgene, Amgen, and Janssen. H.G. received funding from the International Myeloma Foundation – Black Swan and the Dietmar-Hopp-Foundation. The other authors declare no competing interests related to this study.
